Seroatlas · Human Serome Atlas

TNPO2

Transportin-2

Also known as: FLJ12155, IPO3, KPNB2B, TNPO2_HUMAN, TRN2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O14787
Gene
TNPO2
Ensembl
ENSG00000105576
Chromosome
19
Canonical length
897 aa
Protein class
Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters
Subcellular location
Nucleoplasm,Nucleoli

OverviewNCBI Gene

Predicted to enable nuclear import signal receptor activity and nuclear localization sequence binding activity. Predicted to be involved in protein import into nucleus. Predicted to act upstream of or within negative regulation of muscle cell differentiation. Predicted to be active in cytoplasm and nucleus. Implicated in intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

897 residues, UniProt reviewed canonical sequence.

>O14787|TNPO2
     1  MDWQPDEQGL QQVLQLLKDS QSPNTATQRI VQDKLKQLNQ FPDFNNYLIF VLTRLKSEDE
    61  PTRSLSGLIL KNNVKAHYQS FPPPVADFIK QECLNNIGDA SSLIRATIGI LITTIASKGE
   121  LQMWPELLPQ LCNLLNSEDY NTCEGAFGAL QKICEDSSEL LDSDALNRPL NIMIPKFLQF
   181  FKHCSPKIRS HAIACVNQFI MDRAQALMDN IDTFIEHLFA LAVDDDPEVR KNVCRALVML
   241  LEVRIDRLIP HMHSIIQYML QRTQDHDENV ALEACEFWLT LAEQPICKEV LASHLVQLIP
   301  ILVNGMKYSE IDIILLKGDV EEDEAVPDSE QDIKPRFHKS RTVTLPHEAE RPDGSEDAED
   361  DDDDDALSDW NLRKCSAAAL DVLANVFREE LLPHLLPLLK GLLFHPEWVV KESGILVLGA
   421  IAEGCMQGMV PYLPELIPHL IQCLSDKKAL VRSIACWTLS RYAHWVVSQP PDMHLKPLMT
   481  ELLKRILDGN KRVQEAACSA FATLEEEACT ELVPYLSYIL DTLVFAFGKY QHKNLLILYD
   541  AIGTLADSVG HHLNQPEYIQ KLMPPLIQKW NELKDEDKDL FPLLECLSSV ATALQSGFLP
   601  YCEPVYQRCV TLVQKTLAQA MMYTQHPEQY EAPDKDFMIV ALDLLSGLAE GLGGHVEQLV
   661  ARSNIMTLLF QCMQDSMPEV RQSSFALLGD LTKACFIHVK PCIAEFMPIL GTNLNPEFIS
   721  VCNNATWAIG EICMQMGAEM QPYVQMVLNN LVEIINRPNT PKTLLENTGR LTSPSAIPAI
   781  TIGRLGYVCP QEVAPMLQQF IRPWCTSLRN IRDNEEKDSA FRGICMMIGV NPGGVVQDFI
   841  FFCDAVASWV SPKDDLRDMF YKILHGFKDQ VGEDNWQQFS EQFPPLLKER LAAFYGV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TNPO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
73 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 73 nTPM
  • amygdala: 59 nTPM
  • basal ganglia: 55 nTPM
  • cerebellum: 54 nTPM
  • hippocampal formation: 50 nTPM
  • skin: 46 nTPM

Single-cell type

  • adrenal cortex cells: 98 nCPM
  • adrenal medulla cells: 85 nCPM
  • tuft cells: 69 nCPM
  • leydig cells: 66 nCPM
  • peritubular myoid cells: 63 nCPM
  • retinal amacrine cells: 63 nCPM

Immune cell

  • plasmacytoid DC: 1.5 nTPM
  • MAIT T-cell: 1 nTPM
  • naive CD8 T-cell: 1 nTPM
  • naive CD4 T-cell: 0.8 nTPM
  • neutrophil: 0.8 nTPM
  • gdT-cell: 0.6 nTPM

Brain region

  • cerebral cortex: 113 nTPM
  • basal ganglia: 107 nTPM
  • thalamus: 104 nTPM
  • pons: 102 nTPM
  • amygdala: 100 nTPM
  • white matter: 100 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TNPO2.

Disease | AllUniProt

Conditions TNPO2 is implicated in, by any mechanism.

  • Intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies (IDDHISD) MIM:619556

Disease | GeneticClinVar

17 pathogenic / likely-pathogenic of 172 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.13
gnomAD pLI
1
gnomAD missense Z
5.88
DepMap mean gene effect
-0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TNPO2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TNPO2 as an antibody target. Whether an autoantibody or antibody against TNPO2 could matter depends on whether native TNPO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TNPO2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TNPO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TNPO2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...